Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
SAB Biotherapeutics, Inc. - Common Stock
(NQ:
SABS
)
4.180
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about SAB Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
April 13, 2023
Via
Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
April 13, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.
Via
Benzinga
Dow Rises Over 100 Points; Delta Air Lines Earnings Miss Views
↗
April 13, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.43% to 33,790.58 while the NASDAQ rose 1.36% to 12,091.38. The S&P...
Via
Benzinga
SAB Biotherapeutics Unveils New Data From COVID-19 Programs Reinforcing Efficacy Against Variants
↗
September 28, 2022
Via
Benzinga
SAB Biotherapeutics Shifts Focus On Infection Candidate As DoD Contract Closes
↗
August 10, 2022
Via
Benzinga
Why Is SAB Therapeutics Stock Trading Higher Today?
↗
April 13, 2023
SAB Therapeutics (NASDAQ: SABS) shares are trading higher on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 13, 2023
Via
Benzinga
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
↗
April 13, 2023
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
March 29, 2023
On Wednesday, 81 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
March 27, 2023
On Monday, 89 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
March 24, 2023
On Friday, 469 companies hit new 52-week lows.
Via
Benzinga
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
↗
January 18, 2023
SAB Biotherapeutics (NASDAQ: SABS) has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 11, 2023
Via
Benzinga
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
↗
January 10, 2023
SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D)...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
↗
November 29, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
December 29, 2022
On Thursday, 116 companies set new 52-week lows.
Via
Benzinga
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023
↗
November 15, 2022
SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3...
Via
Benzinga
EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants
↗
November 03, 2022
SAB Biotherapeutics Inc (NASDAQ: SABS) presented an overview of its DiversitAb polyclonal platform at the 2022 Plasma Product Biotechnology Conference.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 01, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 10, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 05, 2022
Gainers
Via
Benzinga
Why Sotera Health Shares Are Trading Lower By Around 13%, Here Are 38 Stocks Moving In Wednesday's Mid-Day Session
↗
October 05, 2022
Gainers Pineapple Energy Inc. (NASDAQ: PEGY) shares jumped 104% to $2.9201. Shares of this low-float penny stock closed up about 80% on Tuesday.
Via
Benzinga
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
↗
October 10, 2022
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday.
Via
Benzinga
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 05, 2022
Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million.
Via
Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
↗
October 06, 2022
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
September 15, 2022
Via
Benzinga
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
↗
September 16, 2022
Gainers
Via
Benzinga
SAB Biotherapeutics And 1 Other Stock Under $1 Insiders Are Aggressively Buying
↗
September 15, 2022
The Nasdaq 100 gained by more than 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
August 31, 2022
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
↗
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.